Lipoxygenase and cyclooxygenase pathways and colorectal cancer prevention

Current Colorectal Cancer Reports

Volumn 8, Issue 4, 2012, Pages 316-324

  Rao, Chinthalapally V ^a   Janakiram, Naveena B ^a   Mohammed, Altaf ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Curcumin; Cyclooxygenase; Dual cyclooxygenaselipoxygenase inhibitors; Eicosanoid; Lipoxygenase; Nonsteroidal anti inflammatory drugs; Omega 3 fatty acids; Resolvins

Indexed keywords

1 [3 [3 (4 FLUOROPHENYL)PHENOXY] 1 METHYLALLYL] 1 HYDROXYUREA; 5 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ANTINEOPLASTIC AGENT; BWA 4C; BWB 70C; CELECOXIB; CHEBULAGIC ACID; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LEUKOTRIENE A4; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LIPOXYGENASE; LIPOXYGENASE 5; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PEPTIDOLEUKOTRIENE; PHENYLETHYL 3 METHYL CAFFEATE; PHENYLETHYL CAFFEATE; PROTEIN P53; ROFECOXIB; STAT3 PROTEIN; TERMINALIA CHEBULA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

APOPTOSIS; ARTICLE; ASTHMA; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLIC; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; COUGHING; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG MEGADOSE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; METABOLITE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SORE THROAT; TERMINALIA CHEBULA; THROMBOSIS;

EID: 84869137273     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-012-0146-1     Document Type: Article

References (98)

1. American Cancer Society. Cancer facts and figures 2011 Atlanta; 2011.
2. Potter JD. Nutrition and colorectal cancer. Cancer Causes Control. 1996;7:127-46.
3. Correa P, Haenszel W. The epidemiology of large bowel cancer. Adv Cancer Res. 1978;26:1-141.
4. Wynder EL, Kajitani T, Ishikawa S, et al. Environmental factors in cancer of colon and rectum. Cancer. 1969;23:1210-20.
5. Reddy BS. Diet and colon cancer: evidence from human and animal model studies. In: Reddy BS, Cohen LA, editors. Diet, nutrition and cancer: a critical evaluation, vol. 47. Boca Raton: CRC; 1986.
6. Giovannucci E, Willett WC. Dietary factors and risk of colon cancer. Ann Med. 1995;26:443-52.
7. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer. 2002;2:537-43.
8. Wattenberg LW. An interlocker concept of carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2006;15:1425-6.
9. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res. 2002;62:5119-25.
10. Hong WK, Sporn MB. Recent advance in chemoprevention of cancer. Science. 1997;278:1073-7.
11. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6:130-40.
12. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21:155-64.
13. Rao CV. NSAIDs and chemoprevention-review. Curr Cancer Drug Targets. 2004;4:29-42.
14. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res. 1995;55:1464-72.
15. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology. 1996;110:1259-62.
16. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-7.
17. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res. 2009;2(4):285-7.
18. Thun MJ, Namboodiri MM, Heath Jr. CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-6.
19. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res. 2012;5(2):164-78.
20. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res. 2006;66:4542-6.
21. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376 (9754):1741-50.
22. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis. 1993;14(8):1493-7.
23. Reddy BS, Hirsoe Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-7.
24. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996;56:4566-9.
25. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets. 2004;4:29-42.
26. Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52.
27. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-84.
28. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-102.
29. Solomon DS, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80.
30. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the celecoxib. Am J Cardiol. 2003;92:411-8.
31. Hong SH, Avis I, Vos MD, et al. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999;59:2223-8.
32. Avis I, Hong SH, Martinez A, et al. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001;15:2007-9.
33. Shureiqi I, Lippman SM. Lipoxygenase modulation of reverse carcinogenesis. Cancer Res. 2001;61:6307-12.
34. Ohd JF, Nielsen CK, Campbell J, et al. Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology. 2003;124:57-70.
35. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996;97:806-13.
36. Kargman S, Vickers PJ, Evans JF. A23187 induces translocation of 5-lipoxygenase in osteosarcoma cells. J Cell Biol. 1992;119:1701-9.
37. Boado RJ, Pardridge WM, Vinters HV, Black KL. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc Natl Acad Sci USA. 1992;89:9044-8.
38. Hennig R, Ding XZ, Tong WG, et al. 5-Lipoxygenase and leukotriene B[4] receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161:421-8.
39. Romano M, Catalano A, Nutini M, et al. 5-Lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J. 2001;15:2326-36.
40. Gupta S, Srivastava M, Ahmad N, et al. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer. 2001;91:737-74.
41. Oshima M, Dinchuck JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2. Cell. 1996;87:803-9.
42. Taketo MM. COX-2 and colon cancer. Inflamm Res. 1998;47S: S112-6.
43. Ding XZ, Iversen P, Cluck MW, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun. 1999;261:218-23.
44. Hussey HJ, Tisdale M. Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer. 1994;70:6-10.
45. Hussey HJ, Tisdale MJ. Novel anti-tumor activity of 2,3,5-trimethyl-6-[3- pyridylmethyl]-1,4-benzoquinone [CV-6504] against established murine adenocarcinomas [MAC]. Br J Cancer. 1996;73:1187-92.
46. Hebert MJ, Takano T, Holthofer H, Brady HR. Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids. J Immunol. 1996;157:3105-15.
47. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122:518-23.
48. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55:259-66.
49. Rao CV, Desai D, Rivenson A, et al. Chemoprevention of colon carcinogenesis by phenylethyl-3-methyl caffeate. Cancer Res. 1995;55:2310-5.
50. Shimizu T, Izumi T, Seyama Y, et al. Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proc Natl Acad Sci USA. 1986;83:4175-9.
51. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature. 1990;343:282-4.
52. Peters-Golden M. Cell biology of the 5-lipoxygenase pathway. Am J Respir Crit Care Med. 1998;157:S227-31.
53. Swamy MS, Herzog CR, Rao CV. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res. 2003;63:5239-42.
54. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature. 1994;372:179-82.
55. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med. 1990;323:645-55.
56. Caterna RD, Zampolli A. From asthma to atherosclerosis-5-lipoxynase, leukotrienes and inflammation. N Engl J Med. 2004;350:4-7.
57. Huang L, Zhao A, Wong F, et al. Lekotrine B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arteriosclar Thromb Vasc Biol. 2004;24:1783-8.
58. Soberman RJ, Christmas P. The organization and consequences of eicosanoid signaling. J Clin Invest. 2003;111:1107-13.
59. Radmark OP. The molecular biology and regulation of 5-lipoxygenase. Am J Respir Crit Care Med. 2000;161:S11-5.
60. Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 1990;343:278-81.
61. Bray MA, Ford-Hutchinson AW. Smith M.J. Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins. 1981;22:213-22.
62. Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980;32:517-8.
63. Lewis RA, Ansten KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med. 2000;192:439-46.
64. Sala A, Folco G. Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation? Biochem Biophys Res Commun. 2001;283:1003-66.
65. Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol. 1996;48:46-52.
66. Sala A, Rossoni G, Buccellati C, et al. Formation of sulphidopeptide- leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. Br J Pharmacol. 1993;110:1206-12.
67. Mehrabian M, Allayee H. 5-Lipoxygenanse and arthrosclerosis. Cur Opin Lipidol. 2003;14:447-57.
68. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759-70.
69. Jala VR, Haribabu B. Leukotrienes and atherosclerosis: new roles for old mediators. Trends Immunol. 2004;25:315-22.
70. Helgadottir A, Manolescu A, Thorleifssonet G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004;36:233-9.
71. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146:591-604.
72. Borgdorff P, Tangelder GJ, Paulus WJ. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol. 2006;48:817-23.
73. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415:175-9.
74. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3:2185-92.
75. Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization. J Thromb Haemost. 2007;5:1972-4.
76. Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood. 2002;99:2434-41.
77. Rashid A, Dale GL, Hennebry T. Cold leg in patient with high coated-platelets: Possible association with the use of rofecoxib. J Invasive Cardiol. 2006;18:E181-4.
78. Steele VE, Holmes CA, Hawk ET, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999;8:467-83.
79. Hussey HJ, Tisdale MJ. Inhibition of tumor growth by lipoxygenase inhibitors. Br J Cancer. 1996;74:683-7.
80. Ye YS, Wu WKK, Bruce I, et al. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis. 2005;26:827-34.
81. Li N, Sood S,Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase-2 in Hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res. 2005;11:2089-96.
82. Sirois P, Borgeat P, Lauziere M, et al. Effect of zileuton on the 5-lipoxygnase activity of human whole blood ex vivo. Agents Actions. 1991;34:117-20.
83. Melstrom LG, Bentrem DJ, Salabat MR, et al. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clin Cancer Res. 2008;14(20):6525-30.
84. Bolger JK, Tian W, WolterWR, et al. Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts. Org Biomol Chem. 2011;9(8):2999-3010.
85. Ihara A, Wada K, Yoneda M, et al. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 2007;103(1):24-32.
86. Cheon EC, Khazaie K, Khan MW, et al. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCΔ468 mice. Cancer Res. 2011;7. doi:10.1158/0008-5472.CAN-10-1923.
87. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007;595(1):1-75.
88. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 [COX-2] expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172:111-8.
89. Rao CV, Desai D, Kaul B, et al. Effect of caffeic acid esters on carcinogen-induced mutagenicity and human colon adenocarcinoma cell growth. Chem Biol Interact. 1992;84:277-90.
90. Rao CV, Desai D, Simi B, et al. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res. 1993;53:4182-8.
91. Reddy DB, Reddy TCM, Jyotsna G, et al. Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol. 2009;124(3):506-12. This article demonstrates the effects of a natural agent on COX/LOX inhibition in human colon cancer cells.
92. Cianchi F, Cortesini C, Magnelli L, et al. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther. 2006;5 (11):2716-26.
93. Laufer SA, Augustin J, Dannhardt G, et al. (6,7-Diaryldihydropyrrolizin- 5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J Med Chem. 1994;37:1894-7.
94. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy. Biochem Pharmacol. 2001;62:1433-8.
95. Mohammed A, Janakiram NB, Li Q, et al. Chemoprevention of colon and small intestinal tumorigenesis in APCMin/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res. 2011;4 (12):2015-26. This is a very important study showing the potential chemopreventive effects of the novel dual COX/LOX inhibitor licofelone, which is in clinical trials for treatment of arthritis in APCMin/+ mice. This can lead to potential implications for human colon cancer prevention using agents of this type.
96. Rao CV, Swamy MV, Choi C, et al. Chemoprevention of colon carcinogenesis by licofelone, a novel dual 5-LOX/COX inhibitor in F-344rats. AACR Meeting Abstracts; 2007:11.
97. Janakiram NB, Mohammed A, Rao CV. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev. 2011;30(3-4):507-23. Lipoxins and resolvins are important bioactive lipids that are generated in the arachidonic acid pathway involving the enzymes COX and LOX. This article emphasizes the importance of the regulation of COX and LOX in colon and pancreatic cancer prevention.
98. Arita M, Yoshida M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA. 2005;102:7671-6.